71912-71-5

Basic information

• Product Name: 3-(2-hydroxy-1-ethyl)-1,1'-biphenyl
• Synonyms: 3-(2-hydroxy-1-ethyl)-1,1'-biphenyl
• CAS NO: 71912-71-5
• Molecular Weight: 198.265
• Mol File: 71912-71-5.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: 3-(2-hydroxy-1-ethyl)-1,1'-biphenyl(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(2-hydroxy-1-ethyl)-1,1'-biphenyl(71912-71-5)
• EPA Substance Registry System: 3-(2-hydroxy-1-ethyl)-1,1'-biphenyl(71912-71-5)

Safety Data

• Hazardous Substances Data: 71912-71-5(Hazardous Substances Data)

Upstream product

• 75-21-8 oxirane 
• 2113-57-7 3-bromobiphenyl 
• 75852-28-7 2-biphenyl-3yl-acetic acid methyl ester 
• 10345-87-6 3-phenylcyclohex-2-enone 
• 28229-69-8 2-(3-bromophenyl)ethan-1-ol 
• 98-80-6 phenylboronic acid 
• 594-19-4 tert.-butyl lithium 
• 71912-69-1 (1-Hydroxy-3-phenyl-cyclohex-2-enyl)-acetic acid ethyl ester 
• 147283-87-2 methyl [3-[[(trifluoromethyl)sulfonyl]oxy]phenyl]-acetate 
• 42058-59-3 3-hydroxy-benzeneacetic acid, methyl ester 
• 71912-70-4 ethyl 2-((1,1'-biphenyl)-3-yl)acetate 

Downstream Products

• 71912-46-4 6-phenyl-3,4-dihydronaphthalene-1(2H)-one 
• 71912-51-1 1-(2-Phenylaethyl)-6-phenyl-3.4-dihydronaphthalin 
• 71912-53-3 1-<2-(2-Naphthyl)aethyl>-6-phenyl-3.4-dihydronaphthalin 
• 71912-52-2 1-<2-(1-Naphthyl)aethyl>-6-phenyl-3.4-dihydronaphthalin 
• 71912-54-4 4-(2-Biphenyl-3-yl-ethyl)-7-phenyl-1,2-dihydro-naphthalene 
• 910330-27-7 5-phenyl-3,4-dihydronaphthalen-2(1H)-one 
• 23948-77-8 1,1'-biphenyl-3-ylacetic acid 

Relevant articles and documents

Agent for Preventing or Ameliorating Hearing Impairment

It is to provide an agent for preventing or improving hearing loss, which comprises a low molecular compound which can be produced relatively easily and inexpensively as an active ingredient. One or more compounds selected from the group consisting of compounds represented by the following formulas (I0), (II), and (III) and a pharmaceutically acceptable salt of the compounds when R3 is OH are used as an agent for preventing or improving hearing loss.

Erythropoietin Expression Promoter

The present invention provides an erythropoietin expression-enhancing agent that can cancel the suppression of erythropoietin production or promote erythropoietin production, and a therapeutic or preventive drug for anemia, a liver function-improving agent, an ischemic injury-improving agent, a renal protective agent, and an insulin secretagogue comprising the erythropoietin expression-enhancing agent. The erythropoietin expression-enhancing agent of the present invention comprises one or more compounds selected from the group consisting of compounds represented by the following general formulas (I), (II), and (III) and pharmaceutically acceptable salts thereof when R3 is OH.

Pharmaceutically active benzoquinazoline compounds

Compounds of formula (I) or salts thereof, wherein the dotted line represents a single or double bond, R1is alkyl or amino optionally substituted by alkyl, alkanoyl or benzyl group; R2, R3, R4and R5are the same or different and each is selected from hydrogen, phenyl, halo, nitro, a group S(O)nR8wherein n is the integer 0, 1 or 2 and R8is halo or alkyl or a group NR9R10wherein R9and R10are both hydrogen, a group NR11R12wherein R11and R12are the same or different and each is hydrogen or alkyl, a group OR13wherein R13is hydrogen or C1-4alkyl optionally substituted by halo; a C1-4aliphatic group optionally substituted by a group OR14or NR14R15wherein R14and R15are the same or different and each is hydrogen or alkyl; or two of R2to R5are linked together to form a benzo group, or one of R2to R5is a group -X-Y-R16wherein X is CH2, NR17, CO or S(O)m, and Y is CH2, NR17, O, or S(O)m, or -X-Y- is a group -O-, -NR17-, -CH=CH- or -N=N-, are disclosed as pharmacological agents useful in the treatment of tumours. Pharmaceutical compositions and methods for the preparation of compounds of formula (I) are also described.